Sedana Medical AB (publ) registers AnaConDa in South Korea
Sedana Medical AB’s (publ) (“Sedana Medical” or " the Company") product AnaConDa is approved by K-FDA in South Korea. South Korea is the first country in Asia to approve AnaConDa. The product will be launched in cooperation with the distributor DaeSeuk Med Co. Ltd.
AnaConDa received approval from the South Korean authority K-FDA on 23 February 2017, making South Korea the first market in Asia to approve the AnaConDa technology. Sedana Medical had previously signed a contract with the South Korean distributor DaeSeuk Med Co. Ltd. concerning the rights to market and sell AnaConDa to South Korean hospitals, which is now being initiated.
DaeSeuk has a nationwide sales force that will start training the health care service in using Sedana Medical’s patented innovation AnaConDa, for use in the inhalation sedation of mechanically ventilated patients in intensive care units.
“Though the approval and forthcoming launch of AnaConDa in South Korea, we have established a presence in our first Asian market, which represents a milestone in the company's history and is in line with our strategy. Alongside the ongoing clinical studies we are conducing in Germany, ahead of planned marketing authorisation for the medicinal product IsoConDa® (isoflurane) in Europe, we are building up an international sales organisation of our own in our principal markets, supplemented by external distributors and dealers in other markets. We are already represented in most European countries and in the Middle East, Canada, Australia and now South Korea,” says Christer Ahlberg, CEO of Sedana Medical AB (publ).
For further information, contact:
Christer Ahlberg, CEO Sedana Medical AB (publ)
Mobile: +46 (0)70 – 675 33 30
Email: christer.ahlberg@sedanamedical.com
_________________________
Sedana Medical AB (publ) is a Swedish company that develops, manufactures and sells the medical device AnaConDa. AnaConDa is a medical device for inhalation sedation of mechanically ventilated patients in intensive care units. At the end of 2016, the company initiated a major clinical study to receive market approval in Europe for IsoConDa (isoflurane) for inhalation sedation in intensive care units. The study is expected to end in late 2018. Registration is expected at the end of 2019. Sedana Medical has sales offices in Germany, Spain and France, as well as external distributors in Europe, the Middle East, Canada, Australia and South Korea. The headquarters is based in Danderyd, Sweden and the company has R&D operations in Ireland.
Tags: